# EDGAR Filing Document

**Accession Number:** 0001335105
**File Stem:** 0001493152-25-027219
**Filing Date:** 2025-12
**Character Count:** 7303
**Document Hash:** f28c4791868defd9a567cbee367421bc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-027219.hdr.sgml**: 20251211

**ACCESSION NUMBER**: 0001493152-25-027219

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251208

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251211

**DATE AS OF CHANGE**: 20251211

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001335105
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 202903526
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39717
- **FILM NUMBER:** 251564604

**BUSINESS ADDRESS:**
- **STREET 1:** 433 PLAZA REAL
- **STREET 2:** SUITE 275
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33432
- **BUSINESS PHONE:** 310 203 2902

**MAIL ADDRESS:**
- **STREET 1:** 433 PLAZA REAL
- **STREET 2:** SUITE 275
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33432

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SRKP 7 INC
- **DATE OF NAME CHANGE:** 20050803

?xml version='1.0' encoding='ASCII'?

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 8, 2025

**LIXTE BIOTECHNOLOGY HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

delaware 001-39717 20-2903526 <br> (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification Number)

433 Plaza Real, Suite 275

Boca Raton, Florida 33432

(Address of principal executive offices)

(631) 830-7092

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of Each Class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share | LIXT | The NASDAQ Stock Market, LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On December 8, 2025, Lixte Biotechnology Holdings, Inc. (the "Company"), held its Annual Meeting. At the Annual Meeting, the Company's stockholders were asked to vote upon:

&nbsp;&nbsp;&nbsp;&nbsp;1. The
 election of five directors, each to serve until the Company's 2026 annual meeting of stockholders and until their respective
 successors are duly elected and qualified. The nominees for election were Geordan Pursglove, Jason Sawyer, Dr. Michael Holloway,
 Lourdes Felix and Guy Primus;

&nbsp;&nbsp;&nbsp;&nbsp;2. The
 ratification of the appointment of Weinberg & Company, P.A. as the Company's independent registered public accounting firm
 for the fiscal year ending December 31, 2025; and

&nbsp;&nbsp;&nbsp;&nbsp;3. The
 approval of the amendment to the 2020 Plan to increase the number of shares of common stock available for issuance thereunder from
 2.75 million to 3.5 million.

The results of the matters voted on at the Annual Meeting, based on the presence in person or by proxy of holders of record of 3,117,339 of the 5,635,467 shares of the Company's common stock entitled to vote, were as follows:

&nbsp;&nbsp;&nbsp;&nbsp;1. The
 stockholders approved the election of each of the director nominees to serve until the 2026 annual meeting of stockholders and until
 their respective successors are duly elected and qualified, which required the affirmative vote of the majority of shares of stock
 present, in person or by proxy, and entitled to vote. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | For | Withheld | Broker Non-Votes |
| Geordan Pursglove | 1935249 | 125366 | 1056724 |
| Jason Sawyer | 1926055 | 134560 | 1056724 |
| Dr. Michael Holloway | 2014413 | 46202 | 1056724 |
| Lourdes Felix | 1926094 | 134521 | 1056724 |
| Guy Primus | 2014404 | 46211 | 1056724 |

---

&nbsp;&nbsp;&nbsp;&nbsp;2. The
 stockholders ratified the appointment of Weinberg & Company, P.A. as the Company's independent registered public accounting
 firm for the fiscal year ending December 31, 2025, which required the affirmative vote of the majority of shares of stock present,
 in person or by proxy, and entitled to vote. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| For | Against | Abstain | Broker Non-Votes |
| 3080890 | 36370 | 79 | N/A |

---

&nbsp;&nbsp;&nbsp;&nbsp;3. The
 stockholders approved the amendment of the 2020 Plan which required the affirmative vote of the majority of shares of stock present,
 in person or by proxy, and entitled to vote. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| For | Against | Abstain | Broker Non-Votes |
| 1984980 | 74134 | 1500 | 1056724 |

---

**Item 9.01 Financial Statements and Exhibits**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits. The following exhibits are filed herewith.

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 10.1 | [Amendment to the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan (Incorporated by reference to Annex A to Schedule DEF 14A filed with the SEC on October 27, 2025).](https://www.sec.gov/Archives/edgar/data/1335105/000149315225019697/formdef14a.htm) |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL Document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date: | December 11, 2025 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. |
|  |  | (Registrant) | (Registrant) |
|  |  | *By:* | */s/ Geordan Pursglove* |
|  |  |  | Geordan Pursglove |
|  |  |  | Chairman of the Board and Chief Executive Officer |

---